Generic Name and Formulations:
Oxybutynin chloride 10% (1g/sachet); topical gel; contains alcohol.
Indications for GELNIQUE:
Overactive bladder (OAB) with urge urinary incontinence, urgency, and frequency.
Apply 1g gel (one sachet) once daily to dry, intact skin on abdomen, upper arm/shoulders, or thighs. Rotate application sites; avoid use of same site on consecutive days. Wash hands after application. Avoid washing area/showering for 1hr after application.
Urinary or gastric retention. Uncontrolled narrow angle glaucoma.
Bladder outflow obstruction. Gastrointestinal obstruction. Decreased GI motility. Ulcerative colitis. Intestinal antony. Gastroesophageal reflux. Esophagitis. Hepatic or renal dysfunction. Myasthenia gravis. Controlled narrow angle glaucoma. Discontinue if skin hypersensitivity or angioedema develops; consider discontinuing if anticholineric CNS effects occur. Skin transference: cover application site with clothing after gel has dried if direct contact is anticipated. Exposure to high environmental temperatures. Gel is flammable. Pregnancy (Cat.B). Nursing mothers.
Caution with drugs that can cause or exacerbate esophagitis (eg, bisphosphonates). Additive effects with other anticholinergics.
Dry mouth, application site reactions (eg, pruritus, dermatitis), urinary tract infection, dizziness, nasopharyngitis, fatigue, headache, constipation, other anticholinergic effects (eg, CNS).
Gel (1g/sachet)—30; Gel 3% pump—92g
- 30 packets of 10% cartons (Qty:1)
- appx. price $283.00
- McDonald's and the Microbiome: What Effect Does Junk Food Have on Gut Bacteria?
- When the Doctor is Depressed: One Clinician Tells His Story
- Most Distinctive Causes of Death Mapped by U.S. State
- Spice + Statin Likely Culprit in Patient with Acute Hepatitis
- First Non-Surgical Tx for "Double Chin" Gains FDA Approval
- Antiviral May Tighten Blood-Brain Barrier Against Pathogens
- Better Outcomes for HIV Patients Who Start Treatment Early, Says Study
- DOD: Live Anthrax Accidentally Sent to Nine States, South Korea
- New OTC Lightweight Wearable Launched for Chronic Pain Relief
- FDA: Beware of Embolization With Dermal Fillers